Back

Endogenous adenine is a potential driver of the cardiovascular-kidney-metabolic syndrome

Tamayo, I. M.; Lee, H. J.; Aslam, M. I.; Liu, J.-J.; Ragi, N.; Karanam, V.; Soumya, m.; Saliba, A.; Trevino, E.; Zheng, H.; Lim, S. C.; Lanzer, J. D.; Bjornstad, P.; Tuttle, K. R.; Bedi, K. C.; Margulies, K. B.; Vasan, R. S.; Abdel-Latif, A.; Iyengar, R.; Bopassa, J. C.; Sharma, K.

2024-08-20 cardiovascular medicine
10.1101/2024.08.19.24312277 medRxiv
Show abstract

Mechanisms underlying the cardiovascular-kidney-metabolic (CKM) syndrome are unknown, although key small molecule metabolites may be involved. Bulk and spatial metabolomics identified adenine to be upregulated and specifically enriched in coronary blood vessels in hearts from patients with diabetes and left ventricular hypertrophy. Single nucleus gene expression studies revealed that endothelial methylthioadenosine phosphorylase (MTAP) was increased in human hearts with hypertrophic cardiomyopathy. The urine adenine/creatinine ratio in patients was predictive of incident heart failure with preserved ejection fraction. Heart adenine and MTAP gene expression was increased in a 2-hit mouse model of hypertrophic heart disease and in a model of diastolic dysfunction with diabetes. Inhibition of MTAP blocked adenine accumulation in the heart, restored heart dysfunction in mice with type 2 diabetes and prevented ischemic heart damage in a rat model of myocardial infarction. Mechanistically, adenine-induced impaired mitophagy was reversed by reduction of mTOR. These studies indicate that endogenous adenine is in a causal pathway for heart failure and ischemic heart disease in the context of CKM syndrome.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.